Results 241 to 250 of about 158,005 (297)

Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up. [PDF]

BMJ Open
Connolly D, Fuat A, McCormack T, Mcnally D, Garstang J, Ryan J, Reed A, Robinson D, Catapano AL, Ray KK.   +9 more
europepmc   +1 more source

Medication persistence trajectories among individuals prescribed lipid-lowering therapy in primary care settings: A retrospective cohort study. [PDF]

Br J Clin Pharmacol
Orman Z, Koh JW, Trin C, Ademi Z, Zomer E, Berkovic D, Ilomaki J, Bell JS, Liew D, Reid CM, Lybrand S, Schoeninger B, Talic S.   +12 more
europepmc   +1 more source

LDL-cholesterol control in high-risk individuals: an international obstacle and call for earlier combination lipid-lowering therapy. [PDF]

Arch Med Sci
Razavi AC, Sokolsky M, Blumenthal RS.
europepmc   +1 more source

Adherence to lipid-lowering therapy

Medical Research Journal
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aortopathy: Effects of Lipid-Lowering Therapy

Cardiology in Review, 2023
Aortopathies can be congenital or acquired. Aortic atherosclerosis, abdominal aortic aneurysm, and degenerative aortic stenosis are some of the major manifestations of acquired aortopathy. Dyslipidemia, an imbalance of plasma lipid levels, is strongly associated with common aortopathies.
Matthew, Vollaro, Tanya, Sharma, Mala, Sharma, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

New and Emerging lipid-lowering Therapy

Future Cardiology, 2021
Statins remain the drugs of choice in patients at risk of or with atherosclerotic cardiovascular disease (ASCVD). Statins have limitations that drive the development of investigational agents to manage dyslipidemias and/or reduce ASCVD risk. There are a few small-molecule drugs that have the potential to mitigate ASCVD risk either alone or in ...
James M, Backes, Daniel E, Hilleman
openaire   +2 more sources

Pharmacogenetics of lipid-lowering therapies

Current Atherosclerosis Reports, 2002
Cardiovascular disease is associated with nonmodifiable risk factors such as age, gender, and genetic background, and with modifiable risk factors such as lipid concentrations. Lowering serum lipid levels has been demonstrated to slow the progression of, or even induce regression in, atherosclerosis.
Jose M, Ordovas, Haiqing, Shen
openaire   +2 more sources